Shopping Cart

Remove All

Your shopping cart is currently empty

KY-1044

Catalog No. T81968Cas No. 2489390-15-8

KY-1044 (Alomfilimab; SAR 445256) is a fully human IgG1 monoclonal antibody that targets the inducible costimulatory receptor (ICOS). This compound selectively depletes cells with high ICOS expression through antibody-dependent cellular cytotoxicity (ADCC), mediated by FcγRIIIa engagement. Meanwhile, it acts as a costimulatory molecule for cells with lower ICOS levels, such as CD8+ T Effector cells, via FcγR-dependent clustering. KY-1044 leverages varying ICOS expression levels across T-cell subsets to enhance the intratumoral immune milieu and reinvigorate antitumor immune responses [1].

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Pack Size	Price	Availability	Quantity
1 mg	Inquiry	Backorder
5 mg	Inquiry	Backorder

Bulk & Custom

Add to Cart

Questions

Product Introduction

Bioactivity

Description	KY-1044 (Alomfilimab; SAR 445256) is a fully human IgG1 monoclonal antibody that targets the inducible costimulatory receptor (ICOS). This compound selectively depletes cells with high ICOS expression through antibody-dependent cellular cytotoxicity (ADCC), mediated by FcγRIIIa engagement. Meanwhile, it acts as a costimulatory molecule for cells with lower ICOS levels, such as CD8+ T Effector cells, via FcγR-dependent clustering. KY-1044 leverages varying ICOS expression levels across T-cell subsets to enhance the intratumoral immune milieu and reinvigorate antitumor immune responses [1].
In vitro	KY-1044 (Alomfilimab; SAR 445256; 0-100ng/mL; 4 hours) induces potent antibody-dependent cellular cytotoxicity (ADCC) mediated killing in human natural killer (NK) cells expressing hICOS at an effector to target cell ratio of 5:1, with an EC50 value of 5.6 pmol/L [1].
In vivo	KY-1044 (Alomfilimab; SAR 445256; 10 mg/kg; intraperitoneal injection; bi-weekly for 3 weeks) as a monotherapy, with mIgG2a (effector function-enabled), effectively inhibited tumor growth in lymphoma/multiple myeloma tumor models [1]. In syngeneic mouse tumor models, KY-1044 depleted ICOS high Treg cells and enhanced the ratio of tumor-infiltrating T Eff to Treg cells, leading to increased IFNγ and TNFα secretion by Eff cells [1].
Alias	SAR 445256, Alomfilimab

Chemical Properties

Cas No.

2489390-15-8

Storage & Solubility Information

Storage

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:

For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments

A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent

DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。

Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO TargetMol | reagent

(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.

Preparation method for in vivo formula: Take 50 μL DMSO TargetMol | reagent

main solution, add 300 μLPEG300 TargetMol | reagent

mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O TargetMol | reagent

mix well and clarify

Dose Conversion

You can also refer to dose conversion for different animals. More

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc